Showing: 1 - 10 of 11 RESULTS
Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing the company’s proprietary agonist BMB-101 to the investigational new drug stage enabling safety and toxicology studies for its potential treatment of Dravet syndrome. The biotech firm is selecting BMB-101 as the lead drug candidate in …

Analyst Estimate Briefing Bright Minds Biosciences News Psychedelics

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …

Briefing Bright Minds Biosciences Ian McDonald Psychedelics The Daily Dive Video Series

Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising results of the company’s proprietary BMB-101 drug to treat a rare form of epilepsy, Dravet Syndrome. The chief officer also talks about the firm’s plan to list on the Nasdaq, the common misconceptions on psychedelics, …

Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form of epilepsy, within ongoing late pre-clinical trials. The efficacy was seen in what the company refers to as its 5-HT2C agonist, BMB-101. The …

Briefing Bright Minds Biosciences Gideon Shapiro Psychedelics The Daily Dive Video Series

Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive

Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom is VP of Discovery at Bright Minds Biosciences (CSE: DRUG). A leading scientist in the field of creating novel psychedelics to treat mental health disorders, Dr Shapiro joins us this afternoon to provide us with a deeper understanding of seratonin …

Analyst Estimate Briefing Bright Minds Biosciences Compass Pathways Cybin Inc Field Trip Health Mind Medicine Mindset Pharma Numinus Wellness Inc Psychedelics Small Pharma Inc

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing unmet need in mental health” and that this need has only been growing steadily but has been exacerbated by the COVID-19 pandemic. In this 27 page primer Sepehr Manochehry, their analyst, highlights COMPASS Pathways (NASDAQ: …

Biotech Briefing Bright Minds Biosciences Full Analysis Psychedelics

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to create the next generation of serotonin drugs that will target specific conditions in the brain which lead to mental health problems and neurological ailments. Serotonin is the key hormone which stabilizes our mood, feelings of well-being and happiness. Even more, it allows …

Briefing Bright Minds Biosciences Ian McDonald Psychedelics The Daily Dive Video Series

Bright Minds: The Next Revolution In Mental Health Care – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). Ian joins us today to give the two minute elevator pitch for his company, to give his take on what separates the real operators from the pretenders within the psychedelics space, and to discuss …